Intangible Assets - Additional Information (Detail)	3 Months Ended	6 Months Ended
	Mar. 31, 2017 USD ($)	Mar. 31, 2017 USD ($)
Finite Lived Intangible Assets [Line Items]
Amortization expense	$ 425,107	$ 850,215
Amortization of license agreements remainder of fiscal year 2017	850,214	850,214
Amortization of license agreements in 2018	1,700,429	1,700,429
Amortization of license agreements in 2019	1,700,429	1,700,429
Amortization of license agreements in 2020	1,700,429	1,700,429
Amortization of license agreements in 2021	1,700,429	1,700,429
Amortization of license agreements in 2022	1,700,429	1,700,429
Amortization of license agreements, thereafter	11,962,294	$ 11,962,294
Novartis | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Amortization period of intangible assets		21 years
Finite-lived intangible assets, accumulated amortization	309,178	$ 309,178
Novartis | Patents
Finite Lived Intangible Assets [Line Items]
Amortization period of intangible assets		14 years
Finite-lived intangible assets, accumulated amortization	$ 3,233,833	$ 3,233,833